IM Cannabis Corp. current report, Q1 FY2021

Vollständiges Dokument

Filing Overview

IM Cannabis Corp. filed Form 6-K for April 2021 under the Foreign Private Issuer reporting requirements. The filing was signed April 29, 2021, by Oren Shuster, Chief Executive Officer and Director. The filing identifies Kibbutz Glil Yam, Israel, as the company’s principal executive office.

Business Context and Reporting Period

The filing contains administrative information and identifies two incorporated exhibits: a Business Acquisition Report and the related auditor consent. The supplied filing text does not include the underlying acquisition details or financial statements. The request metadata references March 18, 2021, but the filing itself is dated April 29, 2021 and states that it covers the month of April 2021.

Financial Metrics and Liquidity

The supplied text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, operating results, or other financial metrics.

Material Changes, Guidance, and Risks

  • The filing indicates that a Business Acquisition Report was submitted as Exhibit 99.1, but the transaction terms, acquired business, consideration, financing, and accounting impact are not included in the supplied text.
  • Exhibit 99.2 is a consent from MNP LLP. The scope and conclusions of the consent cannot be determined from the filing text provided.
  • No management guidance, outlook, risk disclosures, contingencies, or unusual financial items are stated in the supplied text.
  • Exhibits 99.1 and 99.2 were incorporated by reference into the company’s Form F-10 registration statement, as amended or supplemented.

Investor Verification Items

  1. Review Exhibit 99.1 for the acquired business, purchase consideration, closing date, financing arrangements, pro forma financial information, and material risks.
  2. Review Exhibit 99.2 for the auditor’s consent and the financial information to which it relates.
  3. Confirm the applicable reporting period, since the supplied metadata and the filing’s stated month are inconsistent.
  4. Obtain the complete exhibits before assessing the transaction’s effect on revenue, earnings, cash flow, debt, and liquidity.